title: Alzheimer's disease and other neurological disorders.
abstract: Menopausal status and estrogen-containing hormone therapy may influence several neurological disorders, including Alzheimer's disease, epilepsy, migraine headache, multiple sclerosis, Parkinson's disease, sleep disorders, and stroke. For most of these illnesses, evidence on hormone therapy is insufficient to guide practice decisions. For stroke, clinical trial evidence indicates that hormone therapy increases risk of cerebral infarction. For women with Alzheimer's disease, estrogen treatment trials have tended to be small and of short duration. Most suggest that estrogen started after the onset of dementia symptoms does not meaningfully improve cognition or slow disease progression. Hormone therapy initiated after age 64 increased all-cause dementia in the Women's Health Initiative Memory Study. Many observational studies, however, report protective associations between hormone use and Alzheimer risk. Apparent risk reduction may represent a bias toward hormone therapy, since hormones are more often prescribed to healthier women. However, when compared to the Women's Health Initiative Memory Study, estrogen exposures in many observational studies reflect hormone initiation at a younger age, closer to the time of menopause. One intriguing hypothesis is that hormone therapy initiated or used during an early critical window may reduce later Alzheimer incidence. Public health implications of this hypothesis are important, but current data are inadequate to decide the issue.
authors: Department of Health Research and Policy, Stanford University, Stanford, California 94305-5405, United States.
authors: V W
authors: VW
authors: Henderson
mesh_terms: D000367:Age Factors; D000544:Alzheimer Disease / Q000517:prevention & control*; D004827:Epilepsy / Q000517:prevention & control; D015914:Estrogen Replacement Therapy; D019317:Evidence-Based Medicine; D005260:Female; D006261:Headache / Q000517:prevention & control; D006801:Humans; D008881:Migraine Disorders / Q000517:prevention & control; D009103:Multiple Sclerosis / Q000517:prevention & control; D010300:Parkinson Disease / Q000517:prevention & control; D012107:Research Design; D012893:Sleep Wake Disorders / Q000517:prevention & control; D020521:Stroke / Q000517:prevention & control; D016387:Women's Health